Skip to main content

Lupus

      Recently the FDA approved deucravacitinib (DEUC), a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in systemic lupus erythematosus.…
      RT @Janetbirdope: Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adher
      2 years ago
      Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
      RT @ericdeinmd: Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
      13 studies included: 70% with low risk o
      2 years ago
      Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE 13 studies included: 70% with low risk of bias BEL improved clinical response at W52 vs non-users OR 1.44 Decrease risk of severe cutaneous flare OR 0.51 Most studies against placebo group @RheumNow https://t.co/2bSwNKRHZZ
      RT @Yuz6Yusof: #ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #l
      #ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
      RT @ericdeinmd: Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH

      7.3% had "severe no
      2 years ago
      Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH 7.3% had "severe non-adherence" by HCQ levels Hazard ratio of flare 3.3, damage 4.26, and death 5.4 Not surprising, but very useful for pt discussion Checking HCQ levels are helpful! @Rheumnow https://t.co/S7P9oTPRGJ
      RT @KDAO2011: Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @r
      2 years ago
      Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
      RT @Yuz6Yusof: #ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a C
      #ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
      RT @EBRheum: Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@M
      2 years ago
      Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon! I'm actually skeptical of this in SLE; are B cells really the answer? w/better targeting & dx selection, this could be game changing #ACR22 https://t.co/Z6t99ZIeMy
      RT @Yuz6Yusof: 2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by
      2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd